Science Daily -
27 Jun 2014 22:37
The brains of Alzheimer's mice treated with the compound RU-505 showed less inflammation and improved blood flow than those of untreated mice. The treated mice also performed better on memory tests, researchers report. For more than a decade, potential Alzheimer's drugs have targeted amyloid-², but, in clinical trials, they have either failed to slow the progression of the disease or caused serious side effects. However, by targeting the protein's ability to bind to a clotting agent in blood, t...
Share this Article
Comment on this Article
Please to comment